Recently, a very elegant study reported that inhibition of kynurenine 3-monooxygenase in peripheral organs, by increasing blood kynurenine levels and brain KYNA content, significantly reduced neurodegeneration in different transgenic models of Huntington’s and Alzheimer’s diseases [46]. This evidence concerns the gene KMO and early-onset autosomal dominant Alzheimer disease.